Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Human OX40 Ligand/TNFSF4 APC-conjugated Antibody, R&D Systems™

Mouse Monoclonal Antibody
Supplier: R&D Systems FAB10541A
This item is not returnable.
View return policy
Description
OX40 Ligand/TNFSF4 Monoclonal specifically detects OX40 Ligand/TNFSF4 in Human samples. It is validated for Flow Cytometry.Specifications
OX40 Ligand/TNFSF4 | |
Monoclonal | |
APC | |
Supplied in a saline solution containing BSA and Sodium Azide. with Sodium Azide | |
CD134 ligand, CD134L, CD252, CD252 antigen, Glycoprotein Gp34, gp34, OX40 antigen ligand, OX40 ligand, OX40L, OX-40L, OX4OL, TAX transcriptionally-activated glycoprotein 1, tax-transcriptionally activated glycoprotein 1 (34kD), tax-transcriptionally activated glycoprotein 1, 34kD, TNFSF4, tumor necrosis factor (ligand) superfamily, member 4, tumor necrosis factor ligand superfamily member 4, TXGP1 | |
Mouse | |
Protein A or G purified from hybridoma culture supernatant | |
RUO | |
7292 | |
Human | |
Purified |
Flow Cytometry | |
159403 | |
Flow Cytometry 10 uL/10^6 cells | |
P23510 | |
TNFSF4 | |
Mouse myeloma cell line NS0-derived recombinant human OX40 Ligand Gln51-Leu183 Accession # P23510 | |
100 Tests | |
Primary | |
Detects human OX40 Ligand in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) APRIL, rhBAFF, rhCD27 Ligand, recombinant mouse (rm) CD27 Ligand, rhCD30 Ligand, rmCD30 Ligand, rhCD40 Ligand, rmEDA, rhFas Ligand, rmFas Ligand, rhGITR Ligand, recombinant cotton rat TNF-alpha , rhTNF-alpha , rmTNF-alpha , recombinant porcine TNF-alpha , recombinant rat TNF-alpha , rhTRAIL, rhTRANCE, rmTRANCE, or rhVEGF is observed. | |
Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 degreesC as supplied. | |
IgG1 |
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction